Merck listed nemtabrutinib in Phase 3 programs before November pipeline update
Key Facts
Merck listed nemtabrutinib, known by the code MK-1026, among its Phase 3 oncology and hematology programs in its fourth-quarter pipeline report, reflecting program status on Nov. 2, 2026. The document places the drug among the company’s clinical programs as of that date and lists it in the BELLWAVE trial group. No documented public evidence confirms that a decision was made on Nov. 17 to stop a particular trial or the entire program. It is therefore not possible to determine whether any subsequent change affected one trial or the full development program. The latest documented status here remains the candidate’s inclusion in the pipeline as of Nov. 2.
Merck’s official pipeline page, which the company said was updated on Nov. 2, 2026, lists trials BELLWAVE-001, BELLWAVE-003, BELLWAVE-008, BELLWAVE-010 and BELLWAVE-011 among the hematologic oncology programs associated with nemtabrutinib. The record covers several trials, not just one study. But the trial listings describe pipeline status when the page was updated and do not, on their own, establish what happened afterward. The available information also does not document a reason for any decision to stop development or identify a party that reviewed clinical results to make one. The scope of the assessment cited in the report attributed to Nov. 17 could not be verified through a reliable public source.
Merck describes nemtabrutinib as an investigational, reversible, non-covalent inhibitor of Bruton’s tyrosine kinase, or BTK, being studied to suppress cancerous B-cell receptor signaling. The company says the drug has activity against both wild-type BTK and BTK pathway mutations, characteristics that place it among approaches targeting a molecular pathway associated with B cells. The candidate remains an investigational drug in development, according to the company. This description sets out the basis for studying the drug, but does not establish a therapeutic outcome or approval for use. In its report dated Nov. 2, Merck listed the drug among its Phase 3 programs, identifying its clinical stage as of that date.
According to Merck’s clinical-trial page, BELLWAVE-003 assesses the safety and efficacy of nemtabrutinib in patients with several types of hematologic malignancies. Those listed include chronic lymphocytic leukemia and small lymphocytic lymphoma, Richter transformation, marginal zone lymphoma, mantle cell lymphoma, follicular lymphoma and Waldenström disease. This description identifies the disease groups covered by this trial, not the scope of every other BELLWAVE trial. The trial page frames the clinical question as an assessment of safety and efficacy. The available information does not establish that this was the scope described in a Nov. 17 statement or that the trial was stopped.
Merck previously presented positive preliminary results from an exploratory analysis of BELLWAVE-003 in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in its materials for the fourth quarter of 2025, at the American Society of Hematology meeting in 2025. Those results provide dated background on the trial and do not, by themselves, update its results in 2026. By contrast, the fourth-quarter 2026 pipeline report listed the drug among Phase 3 programs based on its status on Nov. 2. The available evidence contains no more recent trial results or explanation linking the earlier presentation to any subsequent program change. No documented data are available on Merck’s share price movement in the Nov. 17 session or the market’s response to the report.